In this session at ACR Convergence 2023 (15W112), Ursula Fearon, PhD, Christopher Ritchlin, MD, MPH, and Jose Scher, MD, will highlight recent work that describes key processes in the pathophysiology of psoriatic arthritis, including perturbations in immune and stromal cells and the microbiome. Watch for our article for a snapshot of what these experts have…
The AMA Seeks Physician Input to Inform Medicare Physician Payment
The AMA’s Physician Practice Information Survey is seeking updated data on practice costs to inform Medicare physician payment. If your practice receives a request to participate, complete this important survey to help ensure accurate payment.
Your Invitation Here: Learn How Advocacy Can Help You & Your Practice
Learn how ACR staff and volunteers support the interests of the rheumatology community in public policy efforts related to Medicare reimbursement, step therapy reform, drug pricing, supporting the medical workforce and more.
Annual RheumPAC Matching Campaign & Appreciation Event
From Oct. 15–Nov. 15, all donations to RheumPAC will be amplified by matching contributions, so it’s the best time to make your yearly investment. Donors above the silver level will be invited to a special event at ACR Convergence 2023.
The CMS Reveals First 10 Drugs for Medicare Drug Negotiation
The long-awaited list of the first 10 Part D drugs to be included in the new Medicare Price Negotiation process includes the commonly prescribed rheumatology drugs Enbrel and Stelara. Initial negotiations with the drug manufacturers will begin this fall.
ACR on the Hill: Members Ask Congress to Reduce Barriers to Care
In late September, 80 rheumatologists, rheumatology professionals and patients living with rheumatic disease convened in Washington, D.C., for the ACR’s annual Advocates for Arthritis conference, where they marshaled in support of legislation that would reduce current barriers to care for patients.
FDA Grants Interchangeable Designation to Pfizer’s Abrilada, Biosimilar to AbbVie’s Humira
On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).
Glucocorticoid Use at Any Dose Increases Fracture Risk
The accepted wisdom is that the negative effects of glucocorticoids on bone depend on the dose and treatment duration. Adami et al. conducted this study to determine, in a real-life setting, the risk of fragility fracture associated with the dose of glucocorticoids in patients with inflammatory rheumatic musculoskeletal diseases.
The ACR Launches Rheumatoid Arthritis Measures Toolkit
The new resource offers standardized outcome measures for providers who treat patients with RA, as well as training materials for medical staff to guide accurate and efficient data collection. It also includes video tutorials and sample workflows for different EHR systems.
Updates from the ACR Insurance Subcommittee Chair
The Insurance Subcommittee is working to address coverage and reimbursement challenges facing rheumatology practices. Recent activities include efforts to avoid increased administrative burden associated with specialty medications, support payer coverage of musculoskeletal ultrasounds and protect patient access to biologics.
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 308
- Next Page »